| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Laboratory of Oncologic Research, Orthopaedic Rizzoli Institute; 2 Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy and 3 Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland
Requests for reprints: Katia Scotlandi, Laboratory of Oncologic Research, Orthopaedic Rizzoli Institute, Via Di Barbiano 1/10, 40136 Bologna, Italy. Phone: 39-51-6366760; Fax: 39-51-6366761; E-mail: katia.scotlandi{at}ior.it.
Identification of new drugs is strongly needed for sarcomas. Insulin-like growth factor-I receptor (IGF-IR) was found to provide a major contribution to the malignant behavior of these tumors, therefore representing a very promising therapeutic target. In this study, we analyzed the therapeutic potential of a novel kinase inhibitor of IGF-IR, NVP-AEW541, in Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma, the three most frequent solid tumors in children and adolescents. NVP-AEW541 inhibits IGF-I-mediated receptor activation and downstream signaling. Ewing's sarcoma cells were generally found to be more sensitive to the effects of this drug compared with rhabdomyosarcoma and osteosarcoma, in agreement with the high dependency of this neoplasm to IGF-IR signaling. NVP-AEW541 induced a G1 cell cycle block in all cells tested, whereas apoptosis was observed only in those cells that show a high level of sensitivity. Concurrent exposure of cells to NVP-AEW541 and other chemotherapeutic agents resulted in positive interactions with vincristine, actinomycin D, and ifosfamide and subadditive effects with doxorubicin and cisplatin. Accordingly, combined treatment with NVP-AEW541 and vincristine significantly inhibited tumor growth of Ewing's sarcoma xenografts in nude mice. Therefore, results encourage inclusion of this drug especially in the treatment of patients with Ewing's sarcoma. For the broadest applicability and best efficacy in sarcomas, NVP-AEW541 may be combined with vincristine, actinomycin D, and ifosfamide, three major drugs in the treatment of sarcomas.
This article has been cited by other articles:
![]() |
M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells Ann. Onc., July 17, 2008; (2008) mdn406v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Liu, D. A. Bloom, W. G. Cance, E. V. Kurenova, V. M. Golubovskaya, and S. N. Hochwald FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells Carcinogenesis, June 1, 2008; 29(6): 1096 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Dube, K. J. Rowland, and P. L. Brubaker Glucagon-Like Peptide-2 Activates -Catenin Signaling in the Mouse Intestinal Crypt: Role of Insulin-Like Growth Factor-I Endocrinology, January 1, 2008; 149(1): 291 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. U. Garcia, K. Urbanska, L. Koltowski, K. Reiss, and C. Sell Insulin-Like Growth Factor-I Produced by Seminal Vesicles: Relationship to Intraepithelial Basal Cell Hyperplasia in the Prostate Clin. Cancer Res., June 1, 2007; 13(11): 3140 - 3146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Carrillo, E. Garcia-Aragoncillo, D. Azorin, N. Agra, A. Sastre, I. Gonzalez-Mediero, P. Garcia-Miguel, A. Pestana, S. Gallego, D. Segura, et al. Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth Clin. Cancer Res., April 15, 2007; 13(8): 2429 - 2440. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P. L. Lollini, C. Nanni, F. Hofmann, C. Garcia-Echeverria, P. Picci, et al. Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma Clin. Cancer Res., February 15, 2007; 13(4): 1322 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Riedemann and V M Macaulay IGF1R signalling and its inhibition Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S33 - S43. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tanno, C. Mancini, R. Vitali, M. Mancuso, H. P. McDowell, C. Dominici, and G. Raschella Down-Regulation of Insulin-Like Growth Factor I Receptor Activity by NVP-AEW541 Has an Antitumor Effect on Neuroblastoma Cells In vitro and In vivo. Clin. Cancer Res., November 15, 2006; 12(22): 6772 - 6780. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Whitson, B. A. Jacobson, S. Frizelle, M. R. Patel, D. Yee, M. A. Maddaus, and R. A. Kratzke Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Ann. Thorac. Surg., September 1, 2006; 82(3): 996 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. van Golen, T. S. Schwab, B. Kim, M. E. Soules, S. Su Oh, K. Fung, K. L. van Golen, and E. L. Feldman Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone. Cancer Res., July 1, 2006; 66(13): 6570 - 6578. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Martins, C. Mackintosh, D. H. Martin, M. Campos, T. Hernandez, J.-L. Ordonez, and E. de Alava Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor. Clin. Cancer Res., June 1, 2006; 12(11): 3532 - 3540. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Taulli, C. Scuoppo, F. Bersani, P. Accornero, P. E. Forni, S. Miretti, A. Grinza, P. Allegra, M. Schmitt-Ney, T. Crepaldi, et al. Validation of Met as a Therapeutic Target in Alveolar and Embryonal Rhabdomyosarcoma. Cancer Res., May 1, 2006; 66(9): 4742 - 4749. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hopfner, V. Baradari, A. Huether, C. Schofl, and H. Scherubl The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer, March 1, 2006; 13(1): 135 - 149. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |